Through their laboratory investigation and clinical research, Stanford Hematology Program clinicians are identifying the biologic mechanisms responsible for the development of hematological disorders and developing more effective therapies to address these diseases. Additionally, our doctors are engaged a number of clinical trials through the Southwest Oncology Group and the Eastern Cooperative Oncology Group, as well as in Stanford-based studies.
Innovative research in clinical trials
Stanford has an extensive portfolio of clinical trials using novel therapies and investigational agents for all types of leukemia, multiple myeloma, and myelopfoliferative neoplasms.
Clinical trial participation
Doctors from the Division of Hematology are engaged a number of clinical trials through the Southwest Oncology Group and the Eastern Cooperative Oncology Group, as well as in Stanford-based studies. Some of our current clinical trials include:
- Antibody therapy for chronic lymphocytic leukemia
- Arsenic trioxide for promyelocytic leukemia
- Anti-angiogenesis therapies (treatments that seek to prevent tumors from generating new blood supplies to nourish themselves)
Before beginning treatment, ask your doctor about any clinical trials you should consider. Learn more about clinical trials for cancer patients.
Clinical trial eligibility flowcharts
Eligibility flowcharts map clinical trials to specific types of cancers to determine if a participant is eligible for the particular clinical trial. View all hematology eligibility flowcharts at the Stanford Cancer Institute.